Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes
Top Cited Papers
- 30 October 2015
- journal article
- research article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 30 (3), 666-673
- https://doi.org/10.1038/leu.2015.304
Abstract
Although next-generation sequencing has allowed for the detection of somatic mutations in myelodysplastic syndromes (MDS), the clinical relevance of variant allele frequency (VAF) for the majority of mutations is unknown. We profiled TP53 and 20 additional genes in our training set of 219 patients with MDS or secondary acute myeloid leukemia with findings confirmed in a validation cohort. When parsed by VAF, TP53 VAF predicted for complex cytogenetics in both the training (P=0.001) and validation set (P 40% had a median overall survival (OS) of 124 days versus an OS that was not reached in patients with VAF 40% was an independent covariate (HR, 1.61; PSRSF2 VAF predicted for monocytosis (P=0.003), RUNX1 VAF with thrombocytopenia (P=0.01) and SF3B1 with ringed sideroblasts (P=0.001). Together, our study indicates that VAF should be incorporated in patient management and risk stratification in MDS.Keywords
This publication has 29 references indexed in Scilit:
- TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosisBritish Journal of Haematology, 2013
- Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndromeHaematologica, 2013
- Clonal Architecture of Secondary Acute Myeloid LeukemiaThe New England Journal of Medicine, 2012
- Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasmsBlood, 2011
- SomaticSF3B1Mutation in Myelodysplasia with Ring SideroblastsThe New England Journal of Medicine, 2011
- Frequent pathway mutations of splicing machinery in myelodysplasiaNature, 2011
- Clinical Effect of Point Mutations in Myelodysplastic SyndromesThe New England Journal of Medicine, 2011
- Clinical relevance of JAK2 (V617F) mutant allele burdenHaematologica, 2009
- RUNX1 gene mutation in primary myelodysplastic syndrome – the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcomeBritish Journal of Haematology, 2007
- Configuration of the TP53 Gene as an Independent Prognostic Parameter of Myelodysplastic SyndromeLeukemia & Lymphoma, 2003